Deciphering the crosstalk between cancer stem cells-tumor microenvironment and therapeutic implications in intrahepatic cholangiocarcinoma

Información del proyecto

SteMiCCA

Identificador del acuerdo de subvención: 101024697

DOI

10.3030/101024697

Proyecto finalizado el 10 Agosto 2021

Fecha de la firma de la CE 23 Marzo 2021

Fecha de inicio 1 Septiembre 2021

Fecha de finalización 31 Agosto 2023

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 172 932,48

Aportación de la UE

€ 172 932,48

Coordinado por

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain

Objetivo

Intrahepatic cholangiocarcinoma (iCCA) is the second primary malignancy of the liver with few therapeutic options, late diagnosis, chemotherapy resistance and dismal prognosis. iCCA incidence and mortality increased worldwide in the last decades, linked to the rise of risk factors including non-alcoholic steatohepatitis. iCCA is a highly heterogeneous tumor characterized by a complex and dynamic tumor microenvironment (TME) where stromal cells coexist with cancer and cancer stem cells (CSC). CSCs are a heterogeneous subpopulation of cancer cells capable of tumor initiation, malignant growth and responsible for chemoresistance. The main objective of the “SteMiCCA” project is to identify and target the unexplored CSC-TME interactions in iCCA, aimed to better understand the complex biology and to identify new therapeutic targets for this deadly disease. To achieve this objective, an interdisciplinary approach including in vitro (spheroids and organoids from human and mouse) and in vivo (ICC-models, subcutaneous and xenograft tumor induction) systems; high throughput transcriptomics (scRNA-Seq and RNA-Seq) and bioinformatics will be employed. Considering my strong background and experience in iCCA and TME, and the host institution’s well-recognized expertise in stem cell biology and liver cell plasticity, this proposal envisions a successful reciprocal transfer of knowledge. Moreover, this fellowship will allow me to gain expertise in supervision, intellectual property management, research funding and proposal writing, with the main goal to acquire more competences and reach professional maturity to start my own research line in iCCA. This will also be a first step to strengthen my network and start contributing to European actions such as ESCALON PROJECT 825510 and EURO-CHOLANGIO-NET, created to boost multidisciplinary studies with interest in basic, translational and clinical research in the field of CCA.

Ámbito científico (EuroSciVoc)

• ciencias sociales › sociología › demografía › mortalidad
• ciencias naturales › ciencias biológicas › biología celular
• ciencias médicas y de la salud › biotecnología médica › tecnologías celulares › células madre
• ciencias médicas y de la salud › medicina clínica › oncología

Palabras clave

• intrahepatic cholangiocarcinoma
• cancer stem cell
• tumor microenvironment
• cell heterogeneity
• ligand-receptor interaction
• chemoresistance
• target therapy

Programa(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions PROGRAMA PRINCIPAL
  
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
  

Tema(s)

• MSCA-IF-2020 - Individual Fellowships
  

Régimen de financiación

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Convocatoria de propuestas

H2020-MSCA-IF-2020

Coordinador

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

• Aportación neta de la UEn: € 172 932,48
• Dirección: CARRER ROSSELLO 149 ; 08036 BARCELONA ; España
• Región: Este › Cataluña › Barcelona
• Tipo de actividad: Research Organisations
• Coste total: € 172 932,48